Agata Różycka | Neurogenetics | Best Researcher Award

Published on by Neuroscientists

Dr. Agata Różycka | Neurogenetics | Best Researcher Award

Dr. Agata Różycka, Poznan University of Medical Sciences, Poland.

Dr. Agata Różycka is a molecular neuroscientist and university lecturer at Poznan University of Medical Sciences, specializing in the molecular biology of neurodegeneration, epilepsy, and aging. With a robust academic background that combines molecular biology and pharmacy, she brings together clinical relevance and genetic insight. Her research delves into oxidative stress, genetic polymorphisms, and signal transduction in neurological diseases, with significant contributions to personalized medicine. She is also an accomplished educator, known for delivering high-quality instruction across medical and life science programs. Her scholarly work, published in respected journals and cited widely (h-index 15), continues to impact the fields of neurobiology and molecular diagnostics.

Profile

Orcid

 

🎓 Early Academic Pursuits

Dr. Agata Różycka’s journey in science began with a strong foundation in Molecular Biology and Pharmacy, having completed her MSc and PhD at Adam Mickiewicz University and the Poznan University of Medical Sciences in Poland. From early on, her academic interests were drawn to the molecular intricacies of the brain and human physiology. Her dual institutional training provided her with a broad yet profound grasp of pharmacogenomics, neurobiology, and genetic mechanisms underpinning disease processes. Her graduate years were marked by a passion for decoding the language of DNA and understanding the cellular responses to oxidative stress and genetic variation.

🧠 Professional Endeavors in Neuroscience

Currently a University Lecturer in the Department of Biochemistry and Molecular Biology at the Poznan University of Medical Sciences, Dr. Różycka has dedicated her career to unraveling the molecular foundations of neurological disorders, particularly neurodegeneration, epilepsy, and aging-related changes. Her teaching spans key courses in biochemistry, diagnostics, molecular biology, and laboratory techniques, and she has taught across diverse departments including medicine, nutrition, and biotechnology. Her lectures are known for clarity and depth, consistently earning high evaluations from students, a reflection of her commitment to excellence in scientific education.

🧬 Contributions and Research Focus

Dr. Różycka’s research is defined by its focus on the molecular and genetic mechanisms of neurodegeneration and neurological diseases. She has explored the role of oxidative stress, genetic polymorphisms, and signal transduction pathways in brain aging and epileptogenesis. Her expertise in SNP genotyping, DNA/RNA analysis, and genotoxicity assays has positioned her as a respected figure in the field. Her groundbreaking work on the expression of neuronal nicotinic acetylcholine receptors and the effects of memantine on oxidative DNA damage in aging brains, published in the International Journal of Molecular Sciences in 2025, exemplifies her translational approach to neurodegenerative research.

🧪 Innovation in Molecular Medicine

Beyond basic neuroscience, Dr. Różycka has contributed significantly to the personalized medicine landscape. Her investigations into COMT, MAO-A, and NET gene polymorphisms have improved our understanding of neuropsychiatric conditions like Parkinson’s disease and menopausal depression. Her 2021 study on serotonin polymorphisms and their relation to postoperative pain and nausea in the Journal of Personalized Medicine reflects her interdisciplinary reach, connecting genetics, neurobiology, and clinical practice to enhance patient outcomes.

📚 Academic Influence and Impact

With 682 citations and an h-index of 15, Dr. Różycka’s body of work has earned global recognition in the neuroscientific and biomedical communities. Her contributions are actively followed on platforms such as ORCID, ResearchGate, and Academia.edu, where her network of collaborators and readers continues to grow. Through these forums, she has shaped critical discourse in molecular neuroscience and neuropharmacology, helping researchers worldwide explore new diagnostic and therapeutic frontiers.

🏆 Recognition and Mentorship

Dr. Różycka’s academic excellence extends to mentorship and community engagement. As an educator, she has inspired many budding scientists, fostering critical thinking and hands-on skills in molecular lab techniques. Her reputation for nurturing scientific curiosity and rigor among students is matched by her ability to integrate cutting-edge research into the classroom. Her enduring impact is also evident in the numerous collaborations and citations her work has garnered, reflecting both peer appreciation and scholarly relevance.

🔬 Legacy and Future Contributions

Looking forward, Dr. Różycka aims to delve deeper into epigenetic mechanisms and neuroprotective strategies in aging brains. Her future projects include investigating novel therapeutic targets within cholinergic and serotonergic pathways, with the long-term vision of contributing to early intervention in age-related cognitive decline and epilepsy. As neuroscience continues to evolve, her legacy will be marked by a rare blend of precision science, passionate teaching, and a visionary approach to human health.

Publication

  • Title: Expression of Neuronal Nicotinic Acetylcholine Receptor and Early Oxidative DNA Damage in Aging Rat Brain—The Effects of Memantine
    Authors: Małgorzata Anna Lewandowska, Agata Różycka, Teresa Grzelak, Bartosz Kempisty, Paweł Piotr Jagodziński, Margarita Lianeri, Jolanta Dorszewska
    Year: 2025

 

  • Title: Relationship of Postoperative Pain and PONV after Minimally Invasive Surgery with the Serotonin Concentrations and Receptors’ Gene Polymorphisms
    Authors: Natalia Ignaszak-Kaus, Antoni J. Duleba, Aleksandra Mrozikiewicz, Grażyna Kurzawińska, Agata Różycka, Jan Hauke, Michał Gaca, Leszek Pawelczyk, Paweł Piotr Jagodziński, Piotr Jędrzejczak
    Year: 2021

 

  • Title: Importance of polymorphic variants of phosphatidylethanolamine N-methyltransferase (PEMT) gene in the etiology of intrauterine fetal death in the Polish population
    Authors: Agnieszka Seremak-Mrozikiewicz, Magdalena Barlik, Agata Różycka, Grażyna Kurzawińska, Andrzej Klejewski, Hubert Wolski, Krzysztof Drews
    Year: 2018

 

  • Title: The MAOA, COMT, MTHFR and ESR1 gene polymorphisms are associated with the risk of depression in menopausal women
    Authors: Not fully listed, but includes Agata Różycka (complete list available in source)
    Year: 2016

🔚 Conclusion

Dr. Agata Różycka stands out as a leading figure in the intersection of molecular neuroscience and clinical genetics, with a proven track record of impactful research and dedicated teaching. Her innovative studies on aging brains, gene polymorphisms, and neurotransmitter systems not only advance scientific understanding but also bridge the gap between molecular theory and patient care. With ongoing projects focused on epigenetic regulation and neuroprotective strategies, her work promises to shape the future of neurological health and personalized therapeutics.

 

 

Ivan Zivotic | Molecular Neuroscience | Best Researcher Award

Published on by Neuroscientists

Dr. Ivan Zivotic | Molecular Neuroscience | Best Researcher Award

Dr. Ivan Zivotic, Vinča Institute of Nuclear Sciences, University of Belgrade, Serbia.

Dr. Ivan Životić is a Serbian molecular geneticist whose research focuses on the genetic epidemiology of complex human diseases such as atherosclerosis, congenital kidney anomalies, and chronic inflammatory conditions. With a Ph.D. in Molecular Biology from the University of Belgrade and a master’s background in applied genetics, he has cultivated a strong academic and research foundation. Currently affiliated with the “Vinča” Institute of Nuclear Sciences, he has authored 16 scientific papers and coauthored over 40 abstracts, contributing meaningfully to the fields of genomics and transcriptomics. His expertise lies in deciphering gene-disease associations using modern molecular and computational tools.

Profile

Orcid

🎓 Early Academic Pursuits

Born on July 23, 1986, in Belgrade, Serbia, Dr. Ivan Životić embarked on a promising academic journey rooted in the life sciences. His passion for unraveling the genetic underpinnings of human diseases led him to the Faculty of Biology at the University of Belgrade. He obtained a Master’s degree in Molecular Biology and Physiology in 2011, specializing in applied genetics within the Department of Population Genetics. His master’s thesis explored the role of GST M1 and GST T1 gene deletion polymorphisms in multiple sclerosis, laying the groundwork for his deep engagement in genetic epidemiology. He continued with doctoral studies at the same faculty, where he focused on the molecular biology of eukaryotes. His Ph.D. thesis examined the association between genetic variants on chromosome 9p21 and transcription levels of CDKN2B and HACD4 genes with atherosclerosis and its complications, graduating with an impressive average grade of 9.7.

🧬 Research Focus in Molecular Genetics

Dr. Životić’s research is rooted in molecular genetics with a core focus on the genetic epidemiology of complex human diseases. His scientific curiosity revolves around how genomic and transcriptomic profiles contribute to the development of conditions such as atherosclerosis, congenital kidney anomalies, and chronic inflammatory diseases. His work integrates molecular tools and population studies to understand genetic variants and their influence on disease onset, making valuable contributions to the broader fields of genomics and transcriptomics. His dedication to uncovering genetic risk factors reflects a commitment to improving predictive medicine and tailored healthcare strategies.

🏥 Professional Endeavors in Medical Sciences

Professionally, Dr. Životić holds a distinguished position at the “Vinča” Institute of Nuclear Sciences, a leading Serbian national research institute affiliated with the University of Belgrade. His role within this multidisciplinary environment places him at the forefront of translational research, bridging the gap between laboratory discoveries and clinical applications. Collaborating with esteemed researchers and clinicians, he continually advances the understanding of how molecular mechanisms translate into disease phenotypes, particularly within the realm of cardiovascular and renal health.

📚 Contributions to Scientific Literature

Dr. Životić has authored 16 research papers in internationally recognized SCI journals and coauthored over 40 scientific abstracts presented at prestigious conferences. These publications represent his steady and thoughtful contributions to the academic community. His scholarly output reflects not only the depth of his investigations but also his role in team-based science. His Scopus-indexed h-index of 4 and 54 heterocitations (as of February 12, 2025) demonstrate a growing influence in the field of molecular medical research.

🏆 Accolades and Academic Recognition

Dr. Životić’s academic achievements are complemented by consistent scholarly excellence. With high average grades throughout his university education and a commendable Ph.D. thesis addressing significant clinical concerns, he has earned recognition within his academic circles. His scientific insights into cardiovascular genomics have positioned him as a promising voice among early-career researchers in Serbia’s biomedical community. His educational accomplishments, including supervision under renowned expert Dr. Maja Živković, reflect a foundation built on rigor and mentorship.

🌍 Scientific Impact and Global Relevance

The research conducted by Dr. Životić holds substantial relevance not only within Serbia but also internationally, given the global burden of atherosclerosis and other complex diseases. His work on gene expression, chromosomal variations, and their clinical correlations contributes to a better understanding of disease mechanisms that affect millions worldwide. His interdisciplinary approach, blending genetics, epidemiology, and bioinformatics, is increasingly critical for the development of precision medicine.

🔬 Legacy and Future Contributions

Looking forward, Dr. Životić is poised to make further breakthroughs in the fields of medical genomics and complex disease genetics. As the need for personalized medicine grows, his contributions are expected to inform diagnostic and therapeutic approaches that are tailored to individual genetic backgrounds. With a strong foundation, a collaborative research spirit, and an unwavering focus on human health, Dr. Životić is building a scientific legacy that will inspire future generations of geneticists and medical researchers.

Publication

  • Title: Expression of HMGB1, TGF-β1, BIRC3, ADAM17, CDKN1A, and FTO in Relation to Left Ventricular Remodeling in Patients Six Months after the First Myocardial Infarction: A Prospective Study
    Authors: Jovana Kuveljic, Ana Djordjevic, Ivan Zivotic, Milica Dekleva, Ana Kolakovic, Maja Zivkovic, Aleksandra Stankovic, Tamara Djuric
    Year: 2024

 

  • Title: Gene expression of chemokines CX3CL1 and CXCL16 and their receptors, CX3CR1 and CXCR6, in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis – a pilot study
    Authors: Ljiljana Stojkovic, Aleksandra Stankovic, Ivan Zivotic, Evica Dincic, Dragan Alavantic, Maja Zivkovic
    Year: 2020

 

  • Title: The Effects of Aronia melanocarpa Juice Consumption on the mRNA Expression Profile in Peripheral Blood Mononuclear Cells in Subjects at Cardiovascular Risk
    Authors: Ljiljana Stojković, Ivan Jovanovic, Manja Zec, Ivan Zivotic, Ivan Zivotić, Jovana Kuveljić, Ana Kolaković, Ivana Kolić, Ana Djordjević, Marija Glibetić et al.
    Year: 2020

 

  • Title: CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI
    Authors: Zivotić I, Djurić T, Stanković A, Milasinovic D, Stankovic G, Dekleva M, Marković Nikolić N, Alavantić D, Zivković M
    Year: 2019

 

  • Title: The HACD4 haplotype as a risk factor for atherosclerosis in males
    Authors: Zivotić I, Djurić T, Stanković A, Ivančević I, Končar I, Milasinovic D, Stankovic G, Alavantić D, Zivković M
    Year: 2018

 

  • Title: 9p21 locus rs10757278 is associated with advanced carotid atherosclerosis in a gender-specific manner
    Authors: Zivotić I, Djurić T, Stanković A, Djordjević A, Končar I, Davidović L, Alavantić D, Zivković M
    Year: 2016

 

  • Title: Genetic Variants in the Vicinity of LGALS-3 Gene and LGALS-3 mRNA Expression in Advanced Carotid Atherosclerosis: An Exploratory Study
    Authors: Djordjevic A, Zivkovic M, Stankovic A, Zivotic I, Koncar I, Davidovic L, Alavantic D, Djuric T
    Year: 2016

 

  • Title: The glutathione S-transferase T1 deletion is associated with susceptibility to multiple sclerosis
    Authors: Živković M, Životić I, Dinčić E, Stojković L, Vojinović S, Stanković A
    Year: 2013

 

✅ Conclusion

Dr. Životić exemplifies a new generation of biomedical scientists committed to bridging genetic science with clinical application. His work not only enhances the understanding of disease pathogenesis but also supports the advancement of personalized medicine. With a growing academic presence, a commitment to collaborative research, and a focus on translational impact, Dr. Životić is well-positioned to make lasting contributions to the global scientific community.

Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Published on by Neuroscientists

Dr. Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu, Exegenesis Bio, Inc ,United States.

Zhenhua Wu is a distinguished biotech entrepreneur and scientific leader with over 20 years of experience across the research and development value chain. As the founder, President, and CEO of Exegenesis Bio Inc., he has pioneered accessible, innovative gene therapies for patients with unmet medical needs. His journey spans rigorous academic beginnings, executive leadership in multiple biotechnology companies, and a steadfast commitment to global health advancement. Known for assembling world-class talent and making strategic decisions, Wu has played a key role in shaping the future of gene therapy through both scientific and business excellence.

Profile

Orcid

 

🎓 Early Academic Pursuits

Zhenhua Wu’s journey into the world of biotechnology and gene therapy was shaped by a solid academic foundation rooted in scientific rigor and innovation. During his early academic pursuits, he demonstrated a deep curiosity for biological systems and therapeutic sciences. This intellectual appetite laid the groundwork for his future endeavors in translational medicine, where scientific discovery meets real-world application. His academic training not only honed his research skills but also instilled a lifelong commitment to innovation in the life sciences.

💼 Professional Endeavors

With more than two decades of hands-on experience in the research and development value chain, Zhenhua Wu has established himself as a seasoned leader in biotechnology. He has served in executive roles across a range of biotech companies of various sizes and strategic focuses. In each capacity, he brought visionary leadership, guiding teams to deliver impactful solutions in the biomedical space. His career has been a progressive climb from scientific inquiry to corporate strategy, integrating a robust understanding of science with sharp business acumen.

🧬 Contributions and Research Focus

As a pioneer in the field of gene therapy, Zhenhua Wu’s contributions are both profound and multifaceted. He is the founder and current President and CEO of Exegenesis Bio Inc., a multinational gene therapy company based in Philadelphia, PA. Under his leadership, the company has developed a pipeline of innovative, affordable gene therapies designed to address high unmet medical needs. His research focus lies in advancing next-generation gene therapies that are not only effective but also accessible, aiming to bridge the gap between scientific breakthroughs and patient care.

🏆 Accolades and Recognition

Zhenhua Wu’s impactful career has earned him recognition as a visionary entrepreneur and scientific innovator. Though his biography remains modest in tone, his work has resonated across the biotech sector, attracting significant investment and strategic partnerships. His ability to build and lead a cutting-edge biotech company from the ground up has marked him as a key influencer in gene therapy, with accolades stemming from both industry peers and investors who recognize the value and promise of his work.

🌍 Impact and Influence

Through Exegenesis Bio, Zhenhua Wu has catalyzed a new wave of therapeutic innovation with global reach. His influence extends beyond the lab and boardroom, impacting regulatory conversations, patient advocacy movements, and international biotech development. By forging cross-continental collaborations and assembling a top-tier team of experts, he has ensured that the company is positioned as a global leader in gene therapy solutions, redefining what is possible in patient care and drug development.

🧭 Legacy and Future Contributions

Looking ahead, Zhenhua Wu continues to chart a path focused on expanding access to gene therapy on a global scale. His legacy is being built not only through the therapies under development but also through the culture of scientific integrity, innovation, and purpose that he has instilled in his company. He remains dedicated to mentoring future leaders, cultivating partnerships that push boundaries, and shaping a future where life-altering treatments are within reach for all who need them.

🧠 Visionary Leadership in Gene Therapy

At the heart of Zhenhua Wu’s professional identity is his role as a visionary leader in the fast-evolving field of gene therapy. His ability to connect scientific breakthroughs with patient-focused strategies has transformed Exegenesis Bio into a beacon of hope for countless individuals suffering from genetic diseases. Through his relentless pursuit of innovation, ethical leadership, and commitment to excellence, he continues to redefine what leadership means in the life sciences industry.

Publication

  • Title: Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions
    Authors: Ariazi J, Benowitz A, De Biasi V, den Boer M, Cherqui S, Cui H, Douillet N, Eugenin EA, Favre D, Goodman S, et al.
    Year: 2017

 

  • Title: Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats
    Authors: Wu G, Wu Z, Na S, Hershey JC
    Year: 2015

 

  • Title: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
    Authors: Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, et al.
    Year: 2005

 

🔚 Conclusion

Zhenhua Wu’s career reflects the powerful intersection of science, leadership, and purpose. From building a visionary biotech enterprise to steering the development of transformative therapies, his contributions continue to resonate across the scientific community and healthcare industry. His legacy is not only defined by the innovations he leads today but also by the future he is helping shape—one where advanced gene therapies are more equitable, effective, and globally impactful. Through unwavering dedication and strategic foresight, he stands as a beacon of inspiration in the world of modern biotechnology.